Clinical Trial Update: Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating psilocybin for treatment-resistant post-traumatic stress disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: Halucenex Life Sciences Inc. | Conditions: Treatment Resistant Disorders, Post Traumatic Stress Disorder | Phase 2 | Status: UNKNOWN